Browse Arkansas Code titles and sections
35 U.S.C. § 257 — Supplemental examinations to consider, re-
Federal law — U.S. Code and appendices · legal_authorities
Page 103
TITLE 35—PATENTS
§ 257
1982—Pub. L. 97–247 substituted ‘‘Correction of named
inventor’’ for ‘‘Misjoinder of inventor’’ as section
catchline and, in text, substituted ‘‘Whenever through
error a person is named in an issued patent as the in-
ventor, or through error an inventor is not named in an
issued patent and such error arose without any decep-
tive intention on his part, the Commissioner may, on
application of all the parties and assignees, with proof
of the facts and such other requirements as may be im-
posed, issue a certificate correcting such error’’ for
‘‘Whenever a patent is issued on the application of per-
sons as joint inventors and it appears that one of such
persons was not in fact a joint inventor, and that he
was included as a joint inventor by error and without
any deceptive intention, the Commissioner may, on ap-
plication of all the parties and assignees, with proof of
the facts and such other requirements as may be im-
posed, issue a certificate deleting the name of the erro-
neously joined person from the patent’’, substituted
‘‘The error of omitting inventors or naming persons
who are not inventors shall not invalidate the patent in
which such error occurred if it can be corrected as pro-
vided in this section’’ for ‘‘Whenever a patent is issued
and it appears that a person was a joint inventor, but
was omitted by error and without deceptive intention
on his part, the Commissioner may, on application of
all the parties and assignees, with proof of the facts
and such other requirements as may be imposed, issue
a certificate adding his name to the patent as a joint
inventor’’, and struck out provision that the misjoinder
or nonjoinder of joint inventors not invalidate a pat-
ent, if such error could be corrected as pr
Source: Supplied 2024 U.S. Code historical extraction · 35 U.S.C. § 257
Stored review status: historical_2024_not_currentness_verified. A text match is a research starting point; applicability is not established.
Original supplied file — preserved unchanged
Download original Markdown file
File SHA-256: 54edcfe3fd0a56ea93631c0220b627a5f5ed06cafc25b7862fe12092a95bce77. The original may include catalog metadata, neighboring provisions, or embedded records outside this collection's scope. Search shows only the selected federal record. Historical editions and unverified snapshots are not a statement of current law.
Authority boundary: historical or unconfirmed source not current law verified.
Open the recorded source website ↗
Record provenance
Stable record: federal_law:legal_authorities:usc2024-18829ffe6ed40f21f86355ff
Source file: Laws/federal/codes/united-states-code-2024/title-35/section-257-supplemental-examinations-to-consider-re--06c764a901.md
Pages: Not recorded – Not recorded
Passage SHA-256: 1c0ee22d56dd6574ffa42a11a297fd46893f0546aa0bb3cf03ce821aebbe0b0e
Source location: USCODE-2024-title35-partIII-chap25-sec257.pdf
Stored source content
Page 103
TITLE 35—PATENTS
§ 257
1982—Pub. L. 97–247 substituted ‘‘Correction of named
inventor’’ for ‘‘Misjoinder of inventor’’ as section
catchline and, in text, substituted ‘‘Whenever through
error a person is named in an issued patent as the in-
ventor, or through error an inventor is not named in an
issued patent and such error arose without any decep-
tive intention on his part, the Commissioner may, on
application of all the parties and assignees, with proof
of the facts and such other requirements as may be im-
posed, issue a certificate correcting such error’’ for
‘‘Whenever a patent is issued on the application of per-
sons as joint inventors and it appears that one of such
persons was not in fact a joint inventor, and that he
was included as a joint inventor by error and without
any deceptive intention, the Commissioner may, on ap-
plication of all the parties and assignees, with proof of
the facts and such other requirements as may be im-
posed, issue a certificate deleting the name of the erro-
neously joined person from the patent’’, substituted
‘‘The error of omitting inventors or naming persons
who are not inventors shall not invalidate the patent in
which such error occurred if it can be corrected as pro-
vided in this section’’ for ‘‘Whenever a patent is issued
and it appears that a person was a joint inventor, but
was omitted by error and without deceptive intention
on his part, the Commissioner may, on application of
all the parties and assignees, with proof of the facts
and such other requirements as may be imposed, issue
a certificate adding his name to the patent as a joint
inventor’’, and struck out provision that the misjoinder
or nonjoinder of joint inventors not invalidate a pat-
ent, if such error could be corrected as provided in this
section.
Statutory Notes and Related Subsidiaries
EFFECTIVE DATE OF 2011 AMENDMENT
Amendment by Pub. L. 112–29 effective upon the expi-
ration of the 1-year period beginning on Sept. 16, 2011,
and applicable to proceedings commenced on or after
that effective date, see section 20(l) of Pub. L. 112–29,
set out as a note under section 2 of this title.
EFFECTIVE DATE OF 1999 AMENDMENT
Amendment by Pub. L. 106–113 effective 4 months
after Nov. 29, 1999, see section 1000(a)(9) [title IV, § 4731]
of Pub. L. 106–113, set out as a note under section 1 of
this title.
EFFECTIVE DATE OF 1982 AMENDMENT
Amendment by Pub. L. 97–247 effective six months
after Aug. 27, 1982, see section 17(c) of Pub. L. 97–247, set
out as an Effective Date note under section 294 of this
title.
§ 257. Supplemental examinations to consider, re-
consider, or correct information
(a) REQUEST
FOR
SUPPLEMENTAL
EXAMINA-
TION.—A patent owner may request supple-
mental examination of a patent in the Office to
consider, reconsider, or correct information be-
lieved to be relevant to the patent, in accord-
ance with such requirements as the Director
may establish. Within 3 months after the date a
request for supplemental examination meeting
the requirements of this section is received, the
Director shall conduct the supplemental exam-
ination and shall conclude such examination by
issuing a certificate indicating whether the in-
formation presented in the request raises a sub-
stantial new question of patentability.
(b) REEXAMINATION ORDERED.—If the certifi-
cate issued under subsection (a) indicates that a
substantial new question of patentability is
raised by 1 or more items of information in the
request, the Director shall order reexamination
of the patent. The reexamination shall be con-
ducted according to procedures established by
chapter 30, except that the patent owner shall
not have the right to file a statement pursuant
to section 304. During the reexamination, the
Director shall address each substantial new
question of patentability identified during the
supplemental examination, notwithstanding the
limitations in chapter 30 relating to patents and
printed publication or any other provision of
such chapter.
(c) EFFECT.—
(1) IN GENERAL.—A patent shall not be held
unenforceable on the basis of conduct relating
to information that had not been considered,
was inadequately considered, or was incorrect
in a prior examination of the patent if the in-
formation was considered, reconsidered, or
corrected during a supplemental examination
of the patent. The making of a request under
subsection (a), or the absence thereof, shall
not be relevant to enforceability of the patent
under section 282.
(2) EXCEPTIONS.—
(A) PRIOR
ALLEGATIONS.—Paragraph (1)
shall not apply to an allegation pled with
particularity in a civil action, or set forth
with particularity in a notice received by
the
patent
owner
under
section
505(j)(2)(B)(iv)(II) of the Federal Food, Drug,
and
Cosmetic
Act
(21
U.S.C.
355(j)(2)(B)(iv)(II)), before the date of a sup-
plemental examination request under sub-
section (a) to consider, reconsider, or correct
information forming the basis for the allega-
tion.
(B) PATENT ENFORCEMENT ACTIONS.—In an
action brought under section 337(a) of the
Tariff Act of 1930 (19 U.S.C. 1337(a)), or sec-
tion 281, paragraph (1) shall not apply to any
defense raised in the action that is based
upon information that was considered, re-
considered, or corrected pursuant to a sup-
plemental examination request under sub-
section (a), unless the supplemental exam-
ination, and any reexamination ordered pur-
suant to the request, are concluded before
the date on which the action is brought.
(d) FEES AND REGULATIONS.—
(1) FEES.—The Director shall, by regulation,
establish fees for the submission of a request
for supplemental examination of a patent, and
to consider each item of information sub-
mitted in the request. If reexamination is or-
dered under subsection (b), fees established
and applicable to ex parte reexamination pro-
ceedings under chapter 30 shall be paid, in ad-
dition to fees applicable to supplemental ex-
amination.
(2) REGULATIONS.—The Director shall issue
regulations governing the form, content, and
other requirements of requests for supple-
mental examination, and establishing proce-
dures for reviewing information submitted in
such requests.
(e) FRAUD.—If the Director becomes aware,
during the course of a supplemental examina-
tion or reexamination proceeding ordered under
this section, that a material fraud on the Office
may have been committed in connection with
Page 104
TITLE 35—PATENTS
§ 261
the patent that is the subject of the supple-
mental examination, then in addition to any
other actions the Director is authorized to take,
including the cancellation of any claims found
to be invalid under section 307 as a result of a re-
examination ordered under this section, the Di-
rector shall also refer the matter to the Attor-
ney General for such further action as the At-
torney General may deem appropriate. Any such
referral shall be treated as confidential, shall
not be included in the file of the patent, and
shall not be disclosed to the public unless the
United States charges a person with a criminal
offense in connection with such referral.
(f) RULE
OF CONSTRUCTION.—Nothing in this
section shall be construed—
(1) to preclude the imposition of sanctions
based upon criminal or antitrust laws (includ-
ing section 1001(a) of title 18, the first section
of the Clayton Act, and section 5 of the Fed-
eral Trade Commission Act to the extent that
section relates to unfair methods of competi-
tion);
(2) to limit the authority of the Director to
investigate issues of possible misconduct and
impose sanctions for misconduct in connection
with matters or proceedings before the Office;
or
(3) to limit the authority of the Director to
issue regulations under chapter 3 relating to
sanctions for misconduct by representatives
practicing before the Office.
(Added and amended Pub. L. 112–29, §§ 12(a), 20(j),
Sept. 16, 2011, 125 Stat. 325, 335.)
Editorial Notes
REFERENCES IN TEXT
The first section of the Clayton Act, referred to in
subsec. (f)(1), is classified to section 12 of Title 15, Com-
merce and Trade, and section 53 of Title 29, Labor.
Section 5 of the Federal Trade Commission Act, re-
ferred to in subsec. (f)(1), is classified to section 45 of
Title 15, Commerce and Trade.
AMENDMENTS
2011—Subsec. (c)(2)(B). Pub. L. 112–29, § 20(j), struck
out ‘‘of this title’’ after ‘‘281’’.
Statutory Notes and Related Subsidiaries
EFFECTIVE DATE OF 2011 AMENDMENT
Amendment by section 20(j) of Pub. L. 112–29 effective
upon the expiration of the 1-year period beginning on
Sept. 16, 2011, and applicable to proceedings commenced
on or after that effective date, see section 20(l) of Pub.
L. 112–29, set out as a note under section 2 of this title.
EFFECTIVE DATE
Pub. L. 112–29, § 12(c), Sept. 16, 2011, 125 Stat. 327, pro-
vided that: ‘‘The amendments made by this section [en-
acting this section] shall take effect upon the expira-
tion of the 1-year period beginning on the date of the
enactment of this Act [Sept. 16, 2011] and shall apply to
any patent issued before, on, or after that effective
date.’’
CHAPTER 26—OWNERSHIP AND
ASSIGNMENT
Sec.
261.
Ownership; assignment.
262.
Joint owners.
§ 261. Ownership; assignment
Subject to the provisions of this title, patents
shall have the attributes of personal property.
The Patent and Trademark Office shall main-
tain a register of interests in patents and appli-
cations for patents and shall record any docu-
ment related thereto upon request, and may re-
quire a fee therefor.
Applications for patent, patents, or any inter-
est therein, shall be assignable in law by an in-
strument in writing. The applicant, patentee, or
his assigns or legal representatives may in like
manner grant and convey an exclusive right
under his application for patent, or patents, to
the whole or any specified part of the United
States.
A certificate of acknowledgment under the
hand and official seal of a person authorized to
administer oaths within the United States, or,
in a foreign country, of a diplomatic or consular
officer of the United States or an officer author-
ized to administer oaths whose authority is
proved by a certificate of a diplomatic or con-
sular officer of the United States, or apostille of
an official designated by a foreign country
which, by treaty or convention, accords like ef-
fect to apostilles of designated officials in the
United States, shall be prima facie evidence of
the execution of an assignment, grant or con-
veyance of a patent or application for patent.
An interest that constitutes an assignment,
grant or conveyance shall be void as against any
subsequent purchaser or mortgagee for a valu-
able consideration, without notice, unless it is
recorded in the Patent and Trademark Office
within three months from its date or prior to
the date of such subsequent purchase or mort-
gage.
(July 19, 1952, ch. 950, 66 Stat. 810; Pub. L. 93–596,
§ 1, Jan. 2, 1975, 88 Stat. 1949; Pub. L. 97–247,
§ 14(b), Aug. 27, 1982, 96 Stat. 321; Pub. L. 112–211,
title II, § 201(d), Dec. 18, 2012, 126 Stat. 1535.)
HISTORICAL AND REVISION NOTES
Based on Title 35, U.S.C., 1946 ed., § 47 (R.S. 4898,
amended (1) Mar. 3, 1897, ch. 391, § 5, 29 Stat. 93 [29 Stat.
693], (2) Feb. 18, 1922, ch. 58, § 6, 42 Stat. 391, (3) Aug. 18,
1941, ch. 370, 55 Stat. 634).
The first paragraph is new but is declaratory only.
The second paragraph is the same as in the cor-
responding section of existing statute. The third para-
graph is from the existing statute, a specific reference
to another statute is omitted. The fourth paragraph is
the same as the existing statute but language has been
changed.
Editorial Notes
AMENDMENTS
2012—Pub. L. 112–211 inserted ‘‘The Patent and Trade-
mark Office shall maintain a register of interests in
patents and applications for patents and shall record
any document related thereto upon request, and may
require a fee therefor.’’ at end of first par. and sub-
stituted ‘‘An interest that constitutes an assignment’’
for ‘‘An assignment’’ in fourth par.
1982—Pub. L. 97–247 inserted ‘‘, or apostille of an offi-
cial designated by a foreign country which, by treaty
or convention, accords like effect to apostilles of des-
ignated officials in the United States’’.
1975—Pub. L. 93–596 substituted ‘‘Patent and Trade-
mark Office’’ for ‘‘Patent Office’’.
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Unlawful activities; covered industries; definitions**
(1) Subject to paragraph (2), the following are unlawful, and when found by the Commission to exist shall be dealt with, in addition to any other provision of law, as provided in this section:
(A) Unfair methods of competition and unfair acts in the importation of articles (other than articles provided for in subparagraphs (B), (C), (D), and (E)) into the United States, or in the sale of such articles by the owner, importer, or consignee, the threat or effect of which is—
(i) to destroy or substantially injure an industry in the United States;
(ii) to prevent the establishment of such an industry; or
(iii) to restrain or monopolize trade and commerce in the United States.
(B) The importation into the United States, the sale for importation, or the sale within the United States after importation by the owner, importer, or consignee, of articles that—
(i) infringe a valid and enforceable United States patent or a valid and enforceable United States copyright registered under title 17; or
(ii) are made, produced, processed, or mined under, or by means of, a process covered by the claims of a valid and enforceable United States patent.
(C) The importation into the United States, the sale for importation, or the sale within the United States after importation by the owner, importer, or consignee, of articles that infringe a valid and enforceable United States trademark registered under the Trademark Act of 1946 [[15 U.S.C. 1051](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title15-section1051&num=0&edition=prelim) et seq.].
(D) The importation into the United States, the sale for importation, or the sale within the United States after importation by the owner, i
Source: Supplied U.S. Code snapshot — release unconfirmed · 19 U.S.C. § 1337
Stored review status: release_metadata_unconfirmed. The source passage cites 19 U.S.C. § 1337. This identifies an authority to review, not proof of applicability.
Federal law — U.S. Code and appendices · legal_authorities
Page 117
TITLE 19—CUSTOMS DUTIES
§ 1337
1 See References in Text note below.
act, that the duty or duties shall not exceed a
specified ad valorem rate upon the articles pro-
vided for in such paragraph, no rate determined
under the provisions of this section upon such
articles shall exceed the maximum ad valorem
rate so specified.
(h) Definitions
For the purpose of this section—
(1) The term ‘‘domestic article’’ means an
article wholly or in part the growth or product
of the United States; and the term ‘‘foreign ar-
ticle’’ means an article wholly or in part the
growth or product of a foreign country.
(2) The term ‘‘United States’’ includes the
several States and Territories and the District
of Columbia.
(3) The term ‘‘foreign country’’ means any
empire, country, dominion, colony, or protec-
torate, or any subdivision or subdivisions
thereof (other than the United States and its
possessions).
(4) The term ‘‘cost of production’’, when ap-
plied with respect to either a domestic article
or a foreign article, includes, for a period
which is representative of conditions in pro-
duction of the article: (A) The price or cost of
materials,
labor
costs,
and
other
direct
charges incurred in the production of the arti-
cle and in the processes or methods employed
in its production; (B) the usual general ex-
penses, including charges for depreciation or
depletion which are representative of the
equipment and property employed in the pro-
duction of the article and charges for rent or
interest which are representative of the cost
of obtaining capital or instruments of produc-
tion; and (C) the cost of containers and cov-
erings of whatever nature, and other costs,
charges, and expenses incident to placing the
article in condition packed ready for d
Source: Supplied 2024 U.S. Code historical extraction · 19 U.S.C. § 1337
Stored review status: historical_2024_not_currentness_verified. The source passage cites 19 U.S.C. § 1337. This identifies an authority to review, not proof of applicability.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Necessity of effective approval of application** No person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) or (j) is effective with respect to such drug.
**(b) Filing application; contents**
(1)
(A) Any person may file with the Secretary an application with respect to any drug subject to the provisions of subsection (a). Such persons shall submit to the Secretary as part of the application—
(i) full reports of investigations which have been made to show whether such drug is safe for use and whether such drug is effective in use;
(ii) a full list of the articles used as components of such drug;
(iii) a full statement of the composition of such drug;
(iv) a full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug;
(v) such samples of such drug and of the articles used as components thereof as the Secretary may require;
(vi) specimens of the labeling proposed to be used for such drug;
(vii) any assessments required under [section 355c of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355c&num=0&edition=prelim); and
(viii) the patent number and expiration date of each patent for which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug, and that—
(I) claims the drug for which the applicant submitted the application and is a drug substance (active ingredient) patent or a drug product (formulation or composition) patent; or
(II) claims a method of using such drug for which approv
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 355
Stored review status: release_metadata_unconfirmed. The source passage cites 21 U.S.C. § 355. This identifies an authority to review, not proof of applicability.
Federal law — U.S. Code and appendices · legal_authorities
Page 186
TITLE 21—FOOD AND DRUGS
§ 355
§ 355. New drugs
(a) Necessity of effective approval of application
No person shall introduce or deliver for intro-
duction into interstate commerce any new drug,
unless an approval of an application filed pursu-
ant to subsection (b) or (j) is effective with re-
spect to such drug.
(b) Filing application; contents
(1)(A) Any person may file with the Secretary
an application with respect to any drug subject
to the provisions of subsection (a). Such persons
shall submit to the Secretary as part of the ap-
plication—
(i) full reports of investigations which have
been made to show whether such drug is safe
for use and whether such drug is effective in
use;
(ii) a full list of the articles used as compo-
nents of such drug;
(iii) a full statement of the composition of
such drug;
(iv) a full description of the methods used in,
and the facilities and controls used for, the
manufacture, processing, and packing of such
drug;
(v) such samples of such drug and of the arti-
cles used as components thereof as the Sec-
retary may require;
(vi) specimens of the labeling proposed to be
used for such drug;
(vii) any assessments required under section
355c of this title; and
(viii) the patent number and expiration date
of each patent for which a claim of patent in-
fringement could reasonably be asserted if a
person not licensed by the owner of the patent
engaged in the manufacture, use, or sale of the
drug, and that—
(I) claims the drug for which the applicant
submitted the application and is a drug sub-
stance (active ingredient) patent or a drug
product (formulation or composition) pat-
ent; or
(II) claims a method of using such drug for
which approval is sought or has been granted
in the application.
(B) If an a
Source: Supplied 2024 U.S. Code historical extraction · 21 U.S.C. § 355
Stored review status: historical_2024_not_currentness_verified. The source passage cites 21 U.S.C. § 355. This identifies an authority to review, not proof of applicability.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Request for Supplemental Examination.—** A patent owner may request supplemental examination of a patent in the Office to consider, reconsider, or correct information believed to be relevant to the patent, in accordance with such requirements as the Director may establish. Within 3 months after the date a request for supplemental examination meeting the requirements of this section is received, the Director shall conduct the supplemental examination and shall conclude such examination by issuing a certificate indicating whether the information presented in the request raises a substantial new question of patentability.
**(b) Reexamination Ordered.—** If the certificate issued under subsection (a) indicates that a substantial new question of patentability is raised by 1 or more items of information in the request, the Director shall order reexamination of the patent. The reexamination shall be conducted according to procedures established by chapter 30, except that the patent owner shall not have the right to file a statement pursuant to section 304. During the reexamination, the Director shall address each substantial new question of patentability identified during the supplemental examination, notwithstanding the limitations in chapter 30 relating to patents and printed publication or any other provision of such chapter.
**(c) Effect.—**
(1) **In general.—** — A patent shall not be held unenforceable on the basis of conduct relating to information that had not been considered, was inadequately considered, or was incorrect in a prior examination of the patent if the information was considered, reconsidered, or corrected during a supplemental examination of the patent. The making of a request under subsection (a), or the absence thereof, shall not be relevant to
Source: Supplied U.S. Code snapshot — release unconfirmed · 35 U.S.C. § 257
Stored review status: release_metadata_unconfirmed. Same stored citation; legal effect and authority still require review.